Impaired response to interferon-α2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection

Alessio Aghemo, Maria Grazia Rumi, Roberta Soffredini, Roberta D'Ambrosio, Guido Ronchi, Ersilio Del Ninno, Silvano Gallus, Massimo Colombo

Research output: Contribution to journalArticle

Abstract

Patients with chronic infection with the 3a genotype of hepatitis C virus (HCV) are considered as 'easy-to-treat' with interferon/ribavirin (IFN/RBV), independent of liver disease severity. However, patients with extensive fibrosis or cirrhosis were under-represented in all the registration Phase III trials performed so far. To assess the influence of liver fibrosis on the outcome of anti-HCV therapy, all patients with genotype 3a hepatitis C who were naive to IFN-based therapies, and received RBV combined with standard IFN or pegylated IFN-α2b (peg-IFN-α2b) as standard of care for their disease, were investigated at our centre. A sustained virological response (SVR) was achieved in 68 of 91 patients (75%) independent of IFN type, pretreatment viraemia, clearance of HCV RNA at week 4 and relevant co-morbidities. A SVR was less common in cirrhotics (6 of 17) than in non-cirrhotics (62 of 74; 35% vs 84%; P

Original languageEnglish
Pages (from-to)797-802
Number of pages6
JournalAntiviral Therapy
Volume11
Issue number6
Publication statusPublished - 2006

ASJC Scopus subject areas

  • Pharmacology

Fingerprint Dive into the research topics of 'Impaired response to interferon-α2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection'. Together they form a unique fingerprint.

  • Cite this